ArticleCell death & disease2015
p53 is active in murine stem cells and alters the transcriptome in a manner that is reminiscent of mutant p53.
Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Readout of histone methylation by Trim24 locally restricts chromatin opening by p53.Nature structural & molecular biology · 2023Article
- Robust p53 Stabilization Is Dispensable for Its Activation and Tumor Suppressor Function.Cancer research · 2021Article
- Regulation of p53 by E3s.Cancers · 2021Review
- Amniotic Fluid Cells, Stem Cells, and p53: Can We Stereotype p53 Functions?International journal of molecular sciences · 2019Review
- p53 Is Active in Human Amniotic Fluid Stem Cells.Stem cells and development · 2018Article
- Wild-type p53 binds to MYC promoter G-quadruplex.Bioscience reports · 2016Article
- Histone modifications and p53 binding poise the p21 promoter for activation in human embryonic stem cells.Scientific reports · 2016Article
- Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.The Journal of clinical investigation · 2016Article
- Activity of p53 in human amniotic fluid stem cells increases their potentiality as a candidate for stem cell therapy.Brain circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since it was found that p53 is highly expressed in murine embryonic stem cells, it remained a mystery whether p53 is active in this cell type. We show that a significant part of p53 is localised in the nucleus of murine embryonic stem cells and that the majority of this nuclear p53 is bound to DNA. According to its nuclear localisation, we show that p53 alters the transcriptional program of stem cells. Nevertheless, the anti-proliferative activity of p53 is compromised in stem cells, and this control is due, at least in part, to the high amount of MdmX that is present in embryonic stem cells and bound to p53. Instead of the anti-proliferative activity that p53 has in differentiated cells, p53 controls transcription of pro-proliferative genes in embryonic stem cells including c-myc and c-jun. The impeded anti-proliferative activity of p53 and the induction of certain proto-oncogenes by p53 in murine embryonic stem cells can explain why stem cells proliferate efficiently despite having high levels of p53.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.